Skip to Content
Merck
CN

B1141000

Bleomycin sulfate

European Pharmacopoeia (EP) Reference Standard

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

CAS Number:
9041-93-4
MDL number:
MFCD00070310
UNSPSC Code:
41116107
NACRES:
NA.24

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Bleomycin sulfate, European Pharmacopoeia (EP) Reference Standard

SMILES string

[S+](CCCNC(=O)c1nc([s]c1)c2nc([s]c2)CCNC(=O)C(NC(=O)C(C(O)C(NC(=O)C(NC(=O)c6nc(nc(c6C)N)C(NCC(N)C(=O)N)CC(=O)N)C(O[C@@H]4O[C@H]([C@H]([C@@H]([C@@H]4O[C@H]5O[C@@H]([C@H]([C@@H]([C@@H]5O)O\C(=N\[H])\[O-])O)CO)O)O)CO)c3[nH]cnc3)C)C)C(O)C)(C)C.[S](=O)(=O)(O)O

InChI

1S/C55H83N17O21S3.H2O4S/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6;1-5(2,3)4/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88);(H2,1,2,3,4)/t21?,22?,23?,24?,25?,29-,30+,34?,35?,36?,37+,38+,39-,40-,41?,42-,43-,53+,54-;/m0./s1

InChI key

WUIABRMSWOKTOF-OCBSMOPSSA-N

grade

pharmaceutical primary standard

API family

bleomycin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Bleomycin sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Disclaimer

Sales restrictions may apply.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Carc. 2 - Muta. 1B - Repr. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jie-jie Geng et al.
Biochimica et biophysica acta, 1842(9), 1770-1782 (2014-06-17)
Lung interstitial fibrosis is a chronic lung disease, and few effective therapies are available to halt or reverse the progression of the disease. In murine and human lung fibrosis, the expression of CD147 is increased. However, the role of CD147
Andrea C Lo et al.
International journal of radiation oncology, biology, physics, 88(5), 1011-1018 (2014-03-26)
We report long-term outcomes and complications of craniopharyngioma patients referred to our institution. Between 1971 and 2010, 123 consecutive patients received primary treatment for craniopharyngioma in British Columbia and were referred to our institution. The median age was 30 years
Ying Meng et al.
American journal of respiratory cell and molecular biology, 50(4), 723-736 (2013-10-31)
Accumulating evidence has demonstrated that up-regulation of the angiotensin (Ang)-converting enzyme (ACE)/AngII/AngII type 1 receptor (AT1R) axis aggravates pulmonary fibrosis. The recently discovered ACE2/Ang-(1-7)/Mas axis, which counteracts the activity of the ACE/AngII/AT1R axis, has been shown to protect against pulmonary
Sebastian Willenborg et al.
The Journal of investigative dermatology, 134(7), 2005-2015 (2014-01-11)
Conclusive evidence for the impact of mast cells (MCs) in skin repair is still lacking. Studies in mice examining the role of MC function in the physiology and pathology of skin regenerative processes have obtained contradictory results. To clarify the
Sai Ravi Pingali et al.
Cancer, 120(14), 2122-2129 (2014-04-09)
The objective of this study was to compare the outcomes of patients with classical Hodgkin lymphoma (cHL) who achieved complete remission with frontline therapy and then underwent either clinical surveillance or routine surveillance imaging. In total, 241 patients who were
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service